In Spink5−/−Klk5−/−, Klk5 was genetically ablated on the Netherton background to provide proof of concept for drugging the KLK5 activity for pharmacotherapy of Netherton syndrome and, potentially, other diseases like atopic dermatitis. Here, KLK5 is linked to Netherton syndrome.